1Saito YA, Schoenfeld, Locke GRI 3rd. The epidemiology of irritable bowel syndrome in North America: a systemic review. Am J Gastroenterol, 2002, 97 : 1910-1915.
2Xiong LS, Chen MH, Chen HX, et al. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling. Aliment Pharmarcol Ther, 2004, 19 : 1217-1224.
3Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology, 2002, 123: 2108-2131.
4Devaux M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut, 2002, 51(Suppl 1): i67-i71.
5Drossman DA, Ringel Y, Vogt BA, et al. Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. Gasroenterology, 2003, 124:754-761.
6Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut, 2004, 53:1096-1101.
7Longstreth GF, Thompson WG, Chey WD. Functional bowel disorders// Drossman DA. Rome Ⅲ : the functional gastrointertinal disorders. 2006:487-555.
10Hahn BA, Kirchdoerfer LJ, Fullerton S, et al. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther, 1997, 11:553-559.
5Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology,1997, 112: 2120-2137.
6De Schryver AM, Samsom M. New developments in the treatment of irritable bowel syndrome.Scand J Gastroenterol Suppl, 2000, 41: 38-42.
8Evangelista S. Otilonium bromide: a selective spasmolytic for the gastrointestinal tract. J Int Med Res, 1999, 27: 207-222.
9Battaglia G, Morselli-Labate AM, Camarri E,Francavilla A, De Marco F, Mastropaolo G, Naccarato R. Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Aliment Pharmacol Ther, 1998, 12:1003-1010.
10Glende M, Morselli-Labate AM, Battaglia G,Evangelista S. Extended analysis of a doubleblind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. Eur J Gastroenterol Hepatol, 2002, 14: 1331-1338.
